Neurovance's Series A - II Round

Neurovance raised a round of funding on April 03, 2014.

Neurovance is a privately held, clinical-stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders. Neurovance is developing centanafadine (CTN, for…

Articles about Neurovance's Series A - II Round: